Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Open-label Clinical Study to Evaluate the Tolerability and Safety of an Initiation Dose of 5 mg of Vericiguat in Participants With Chronic Heart Failure With Reduced Ejection Fraction

NCT06195930 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06195930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06195930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Open-label Clinical Study to Evaluate the Tolerability and Safety of an Initiation Dose of 5 mg of Vericiguat in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
April 18, 2024
Completion date
July 29, 2024
Enrollment
106 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure with reduced ejection fraction